This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response (AMELIORATE)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Pere Gines, Hospital Clinic of Barcelona Identifier:
First received: February 9, 2012
Last updated: August 17, 2016
Last verified: August 2016
Observe the effect of terlipressin on renal function in patients with SHR type I adjusting the dose based on hemodynamic response.

Condition Intervention Phase
Cirrhosis Hepatorenal Syndrome Type I Drug: Terlipressin and albumin Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response

Resource links provided by NLM:

Further study details as provided by Pere Gines, Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Changes in arterial pressure and creatinine [ Time Frame: 4 months ]

Secondary Outcome Measures:
  • Changes in plasmatic renin activity and aldosterone and noradrenaline concentration. [ Time Frame: 4 months ]
  • Treatment-related adverse events [ Time Frame: 4 months ]
  • Hepatorenal Syndrome reversion due to hemodynamic changes. [ Time Frame: 4 months ]

Estimated Enrollment: 40
Study Start Date: April 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: terlipressin Drug: Terlipressin and albumin

Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase < 10 mmHg and the creatinine values decrease <25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.

Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with hepatorenal syndrome type 1.
  • Signed informed consent.
  • No exclusion criteria.
  • At least 18 years old
  • Negative pregnancy test in serum or urine in women of childbearing age, and agree to use adequate contraception since at least 14 days prior to the first dose of study drug until 14 days after the last.

Exclusion Criteria:

  • Hepatocellular carcinoma: exclusion of patients with hepatocellular carcinoma who present more than 3 nodules, single nodule larger than 5 cm, tumor portal thrombosis or extrahepatic tumor spread.
  • Active bacterial infection with symptoms of systemic inflammatory response (fever, tachycardia, tachypnea, hypotension, septic or blood count).
  • Cardiac or respiratory failure clinically significant.
  • Clinically significant peripheral artery disease.
  • A history of ischemic heart disease.
  • Hypersensitivity to terlipressin and / or albumin or any of the excipients.
  • Pregnancy.
  • Septic shock.
  • Chronic renal failure.
  • Women in lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01530711

Corporació Sanitària Parc Taulí
Sabadell, Barcelona, Spain, 08208
Hospital Moisés Broggi
Sant Joan Despí, Barcelona, Spain, 08970
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain, 08036
Hospital del Mar
Barcelona, Spain, 08036
Hospital Vall d´Hebron
Barcelona, Spain, 08036
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08041
Sponsors and Collaborators
Pere Gines
Principal Investigator: German Soriano Pastor, MD
Principal Investigator: Juan Cordoba, MD
Principal Investigator: Isabel Cirera Lorenzo, MD
Principal Investigator: Marta Martín Llahí, MD
Principal Investigator: Jordi Sánchez Delgado, MD
  More Information

Responsible Party: Pere Gines, MD, PhD, Hospital Clinic of Barcelona Identifier: NCT01530711     History of Changes
Other Study ID Numbers: AMELIORATE
Study First Received: February 9, 2012
Last Updated: August 17, 2016

Additional relevant MeSH terms:
Hepatorenal Syndrome
Pathologic Processes
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Antihypertensive Agents
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs processed this record on September 20, 2017